Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/21011Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tsatsoulis, A. | en |
| dc.contributor.author | Shalet, S. M. | en |
| dc.contributor.author | Morris, I. D. | en |
| dc.contributor.author | de Kretser, D. M. | en |
| dc.date.accessioned | 2015-11-24T19:12:04Z | - |
| dc.date.available | 2015-11-24T19:12:04Z | - |
| dc.identifier.issn | 0301-0163 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/21011 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Antineoplastic Combined Chemotherapy Protocols/adverse effects | en |
| dc.subject | Biological Markers/blood | en |
| dc.subject | Follicle Stimulating Hormone/blood | en |
| dc.subject | Humans | en |
| dc.subject | Inhibins/*blood | en |
| dc.subject | Luteinizing Hormone/blood | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Oligospermia/etiology | en |
| dc.subject | Sertoli Cells/drug effects/*physiology/radiation effects | en |
| dc.subject | Testis/*drug effects/*radiation effects | en |
| dc.subject | Testosterone/blood | en |
| dc.title | Immunoactive inhibin as a marker of Sertoli cell function following cytotoxic damage to the human testis | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/2129227 | - |
| heal.identifier.secondary | http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000181836 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1990 | - |
| heal.abstract | Sertoli and Leydig cell functions were evaluated in men with testicular damage due either to cytotoxic chemotherapy (CCT) or radiotherapy (XRT). Serum immunoactive inhibin, follicle-stimulating hormone (FSH), luteinizing hormone (LH) and testosterone concentrations were measured in 15 men (19-50 years) who had received 6-10 courses of combination CCT (mustine, vinblastine, procarbazine and prednisolone) for Hodgkin's disease 1-8 years earlier and 18 men (21-49 years) who had undergone unilateral orchidectomy for testicular seminoma followed by XRT (30 Gy) to the remaining testis, 1-4 years earlier. Normal men (n = 16, 19-36 years) acted as controls. Median inhibin (422 U/l) and testosterone (16.0 nmol/l) levels in the CCT-treated group were not significantly different from controls, whereas median FSH (14.5 IU/l) and LH (10.0 IU/l) levels were higher (p less than 0.0001 and p less than 0.001) than normal (2.9 and 5.5 IU/l). The median inhibin/FSH (I/FSH) ratio in the patients was lower (p less than 0.0001) than in the controls (33.8 vs. 187.0) as was the testosterone/LH (T/LH) ratio (1.7 vs. 3.8, p less than 0.001). In the XRT-treated group, both median inhibin (194.5 U/l) and testosterone (12.7 nmol/l) levels were lower (p less than 0.0001 and p less than 0.01) than normal (532.8 U/l and 20.0 nmol/l) in the presence of greatly elevated FSH (26.0 IU/l) and LH (14.5 IU/l) levels. In conclusion, CCT-induced testicular damage is associated with subtle Sertoli and Leydig cell dysfunction demonstrated by the reduced I/FSH and T/LH ratios; however, compensatory mechanisms maintain normal testosterone and inhibin levels.(ABSTRACT TRUNCATED AT 250 WORDS) | en |
| heal.journalName | Horm Res | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
